Scholarlink

Purpose <p>Cholangiocarcinoma (CCA), a malignancy of the hepatobiliary system, lacks predictive biomarkers due to the scarcity of publicly available datasets. Disulfidptosis, a recently identified form of regulated cell death, is triggered by disulfide accumulation in SLC7A11-high tumor cells under glucose deprivation. Its role in CCA, however, remains unexplored.</p> Methods <p>We systematically evaluated the transcriptional and mutational profiles of disulfidptosis-regulating genes (DRGs) in CCA. Based on their expression, distinct disulfidptosis clusters (CDR clusters) were defined. Differentially expressed genes (DEGs) derived from these clusters were used to classify the samples into Gene Cluster A and Gene Cluster B. A subsequent prognostic risk model was then developed. Clinical characteristics, immune cell infiltration (assessed via Immune Score and ESTIMATE Score), and drug sensitivities were compared between high- and low-risk groups.</p> Results <p>Most disulfidptosis-regulating genes exhibited significant differential expression and prognostic value in CCA. DEG analysis defined Gene Clusters A/B. Four key genes—RTN4RL1, SLC13A1, FOSL1, and COX6B2—were identified to construct the prognostic model. The high-risk group exhibited significantly poorer overall survival in both the training cohort (<i>n</i> = 262; AUC 1–3 years: 0.796–0.819) and an independent external validation cohort (<i>n</i> = 30; AUC 1–3 years: 0.804–0.868). Multivariate analysis confirmed the risk score as an independent prognostic factor. The high-risk group demonstrated significantly elevated Immune Scores and ESTIMATE Scores. Drug sensitivity analysis revealed differential responses between risk groups, identifying potential therapeutic agents for CCA. qPCR validation in independent CCA patient specimens confirmed significant upregulation of high-risk genes (FOSL1, COX6B2) and downregulation of low-risk genes (RTN4RL1, SLC13A1) in tumor tissues, corroborating our bioinformatic findings.</p> Conclusion <p>This represents the first systematic exploration of the prognostic associations and tumor microenvironment implications of disulfidptosis-related genes (DRGs) in CCA. Our findings elucidate the role of disulfidptosis, reveal its association with the tumor immune microenvironment, and our in silico drug sensitivity analysis generates hypotheses for potential therapeutic strategies that may be tested in future preclinical studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comprehensive analysis of disulfidptosis-related genes identifies clinically actionable prognostic biomarkers in cholangiocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月16日

查看全文
  • Rongchun Xing,
  • Chongyuan Chen,
  • Yu Yang,
  • Hang Zhou,
  • Mingzheng Hu

摘要

Purpose

Cholangiocarcinoma (CCA), a malignancy of the hepatobiliary system, lacks predictive biomarkers due to the scarcity of publicly available datasets. Disulfidptosis, a recently identified form of regulated cell death, is triggered by disulfide accumulation in SLC7A11-high tumor cells under glucose deprivation. Its role in CCA, however, remains unexplored.

Methods

We systematically evaluated the transcriptional and mutational profiles of disulfidptosis-regulating genes (DRGs) in CCA. Based on their expression, distinct disulfidptosis clusters (CDR clusters) were defined. Differentially expressed genes (DEGs) derived from these clusters were used to classify the samples into Gene Cluster A and Gene Cluster B. A subsequent prognostic risk model was then developed. Clinical characteristics, immune cell infiltration (assessed via Immune Score and ESTIMATE Score), and drug sensitivities were compared between high- and low-risk groups.

Results

Most disulfidptosis-regulating genes exhibited significant differential expression and prognostic value in CCA. DEG analysis defined Gene Clusters A/B. Four key genes—RTN4RL1, SLC13A1, FOSL1, and COX6B2—were identified to construct the prognostic model. The high-risk group exhibited significantly poorer overall survival in both the training cohort (n = 262; AUC 1–3 years: 0.796–0.819) and an independent external validation cohort (n = 30; AUC 1–3 years: 0.804–0.868). Multivariate analysis confirmed the risk score as an independent prognostic factor. The high-risk group demonstrated significantly elevated Immune Scores and ESTIMATE Scores. Drug sensitivity analysis revealed differential responses between risk groups, identifying potential therapeutic agents for CCA. qPCR validation in independent CCA patient specimens confirmed significant upregulation of high-risk genes (FOSL1, COX6B2) and downregulation of low-risk genes (RTN4RL1, SLC13A1) in tumor tissues, corroborating our bioinformatic findings.

Conclusion

This represents the first systematic exploration of the prognostic associations and tumor microenvironment implications of disulfidptosis-related genes (DRGs) in CCA. Our findings elucidate the role of disulfidptosis, reveal its association with the tumor immune microenvironment, and our in silico drug sensitivity analysis generates hypotheses for potential therapeutic strategies that may be tested in future preclinical studies.